Sana Biotechnology is no longer a sprawling multi-program cell-therapy story. It is a narrowed bet that hypoimmune editing, already shown to keep donor islets alive in a single patient without immunosuppression, can be scaled into a stem-cell product before the cash clock forces another large equity sale. The company spent the second quarter converting that scientific claim into a Mayo Clinic development partnership and a thicker cash balance, while the same quarterly filing still carried substantial doubt about going concern. The market is paying a mid-nine-figure enterprise value for a platform that has one investigator-sponsored patient, no company-sponsored investigational new drug application accepted yet, and an in-vivo CAR T program whose first human data slipped after China timing stretched out.
Cash and marketable securities rose to $160 million at mid-year, funded by $93 million of net equity proceeds in the quarter. That raise mixed an at-the-market stock sale with a $25 million Mayo Clinic purchase. GAAP net loss narrowed because last year's print carried a large facility impairment, not because the cash operating machine suddenly became cheap. Non-cash fair-value charges on Cobalt Biomedicine contingent consideration and success-payment liabilities still swing the reported loss with the stock price. The accounting improvement is real on the impairment comparison and less informative on the cash question that actually funds the lead programs.
Fourteen-month follow-up from the Uppsala investigator-sponsored islet graft, published as a New England Journal of Medicine letter, showed persistent C-peptide and graft signal on imaging with no immunosuppression. Management still talks about a company-sponsored diabetes filing and a first-in-human start as early as this year, while a September conference appearance put first in-vivo CAR T data into the first half of next year after a China regulatory delay. The investment question is whether hypoimmune proof plus a Mayo protocol partnership is enough to finance the next stretch without another heavy stock sale, or whether the going-concern paragraph is the more honest description of the residual claim.